Regenxbio Inc
NASDAQ:RGNX
Regenxbio Inc
Gross Profit
Regenxbio Inc
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Regenxbio Inc
NASDAQ:RGNX
|
Gross Profit
$49.3m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Gross Profit
$36.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Gross Profit
$20.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Gross Profit
$19.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Gross Profit
$8.8B
|
CAGR 3-Years
16%
|
CAGR 5-Years
26%
|
CAGR 10-Years
26%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Gross Profit
$11.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
See Also
What is Regenxbio Inc's Gross Profit?
Gross Profit
49.3m
USD
Based on the financial report for Mar 31, 2024, Regenxbio Inc's Gross Profit amounts to 49.3m USD.
What is Regenxbio Inc's Gross Profit growth rate?
Gross Profit CAGR 5Y
-9%
Over the last year, the Gross Profit growth was -26%. The average annual Gross Profit growth rates for Regenxbio Inc have been -25% over the past three years , -9% over the past five years .